eribulin
Showing 1 - 25 of 212
HER2-positive Breast Cancer Trial in Guanzhou (Eribulin mesylate injection?Pertuzumab?Trastuzumab)
Recruiting
- HER2-positive Breast Cancer
- Eribulin mesylate injectionăPertuzumabăTrastuzumab
-
Guanzhou, Guangdong, ChinaLI YuDong
Jul 13, 2023
Refractory Solid Tumors Trial in Houston (Eribulin, Irinotecan, Temozolomide)
Recruiting
- Refractory Solid Tumors
- Eribulin
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 22, 2023
Ovarian Carcinosarcoma, Uterine Carcinosarcoma Trial (Eribulin Mesylate, Pembrolizumab)
Not yet recruiting
- Ovarian Carcinosarcoma
- Uterine Carcinosarcoma
- Eribulin Mesylate
- Pembrolizumab
- (no location specified)
Jan 31, 2023
Eribulin-Based Regimen Versus Other Chemotherpy in
Active, not recruiting
- Breast Cancer
- Eribulin-Based Regimen
- +2 more
-
Fuzhou, Fujian, ChinaFujian Cancer Hospital
Jul 18, 2023
Breast Cancer Trial in Tampa (Eribulin, Carboplatin)
Completed
- Breast Cancer
- Eribulin
- Carboplatin
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Oct 28, 2022
Leiomyosarcoma, Liposarcoma, Soft Tissue Sarcoma Adult Trial in Taipei (Eribulin, Lenvatinib)
Active, not recruiting
- Leiomyosarcoma
- +3 more
- Eribulin
- Lenvatinib
-
Taipei, Taiwan
- +1 more
Dec 27, 2022
Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Trial in Boston (Eribulin, Adriamycin,
Active, not recruiting
- Inflammatory Breast Cancer
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Eribulin
- +2 more
-
Boston, Massachusetts
- +1 more
Nov 28, 2022
Triple Negative Breast Cancer Trial in Beijing (Eribulin Mesylate, Lobaplatin)
Recruiting
- Triple Negative Breast Cancer
- Eribulin Mesylate
- Lobaplatin
-
Beijing, Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Sep 15, 2022
HER2 Negative Breast Cancer Trial in Zhenzhou (Eribulin plus Tucidinostat)
Not yet recruiting
- HER2 Negative Breast Cancer
- Eribulin plus Tucidinostat
-
Zhenzhou, ChinaHenan Cancer Hospital
May 26, 2022
Metastatic Breast Cancer Trial in Changsha (Eribulin Mesylate, Anlotinib)
Recruiting
- Metastatic Breast Cancer
- Eribulin Mesylate
- Anlotinib
-
Changsha, Hunan, ChinaHunan Cancer Hospital
May 4, 2022
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Terminated
- Anatomic Stage IV Breast Cancer AJCC v8
- +2 more
- Bintrafusp Alfa
- Eribulin Mesylate
-
Houston, Texas
- +1 more
Oct 27, 2022
Liposarcoma, Malignant Abdominal Tumor, Malignant Retroperitoneal Tumor Trial in Portland (drug, radiation, other, procedure)
Recruiting
- Liposarcoma
- +5 more
- Eribulin Mesylate
- +5 more
-
Portland, OregonOHSU Knight Cancer Institute
Oct 17, 2022
TNBC - Triple-Negative Breast Cancer Trial in Beijing (Eribulin, anti-PD-1 antibody)
Recruiting
- TNBC - Triple-Negative Breast Cancer
- Eribulin
- anti-PD-1 antibody
-
Beijing, Beijing, ChinaThe Fifth Medical Center of PLA General Hospital
May 29, 2022
Breast Inflammatory Carcinoma, Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma Trial in Houston
Recruiting
- Breast Inflammatory Carcinoma
- +2 more
- Eribulin Mesylate
- Grapiprant
-
Houston, TexasM D Anderson Cancer Center
Jun 27, 2022
Metastatic Breast Cancer Trial in Italy (Eribulin Mesylate, Capecitabine)
Active, not recruiting
- Metastatic Breast Cancer
- Eribulin Mesylate
- Capecitabine
-
Brescia, Italy
- +24 more
Apr 18, 2023
Solid Tumor Trial in Buffalo (Eribulin ORA)
Recruiting
- Solid Tumor
- Eribulin ORA
-
Buffalo, New YorkRoswell Park Cancer Institute
Feb 15, 2022
Breast Cancer, Metastatic Triple-Negative Breast Cancer Trial in United States (Eribulin, SDX-7320, Placebo)
Recruiting
- Breast Cancer
- Metastatic Triple-Negative Breast Cancer
- Eribulin
- +2 more
-
Basking Ridge, New Jersey
- +6 more
Oct 4, 2022
Angiosarcoma, Epithelioid Hemangioendothelioma Trial in Boston (Eribulin)
Recruiting
- Angiosarcoma
- Epithelioid Hemangioendothelioma
- Eribulin
-
Boston, Massachusetts
- +1 more
Feb 14, 2022
Metastatic Malignant Tumor in the Adult Brain, Primary Brain Tumor Trial in Duarte (procedure, drug, other)
Active, not recruiting
- Metastatic Malignant Neoplasm in the Adult Brain
- Primary Brain Tumor
- Therapeutic Conventional Surgery
- +4 more
-
Duarte, CaliforniaCity of Hope Medical Center
Mar 16, 2022
HER2-negative Breast Cancer Trial (Gemcitabine combined with eribulin)
Not yet recruiting
- HER2-negative Breast Cancer
- Gemcitabine combined with eribulin
- (no location specified)
Mar 2, 2022
Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor-negative Trial in Duarte, Rancho Cucamonga, South Pasadena
Completed
- Estrogen Receptor Negative
- +4 more
- everolimus
- +3 more
-
Duarte, California
- +2 more
Jun 6, 2022
Breast Cancer, Breast Adenocarcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Trial in Bronx (Rebastinib,
Terminated
- Breast Cancer
- +4 more
- Rebastinib
- +2 more
-
Bronx, New YorkMontefiore Medical Center
Mar 23, 2022
Breast Cancer Trial in Boston (Eribulin Mesylate, Pembrolizumab)
Active, not recruiting
- Breast Cancer
- Eribulin Mesylate
- Pembrolizumab
-
Boston, Massachusetts
- +2 more
Apr 18, 2022